
|Articles|October 1, 2019
- Pharmaceutical Executive-10-01-2019
- Volume 39
- Issue 10
Pharmaceutical Executive, October 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive October 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Tech Tour for the C-Suite: Pharma’s Digital Futureover 6 years ago
It Starts with a Scribbleover 6 years ago
Olivier Laureau, Servier: Free to Grow, Innovateover 6 years ago
Corey McCann: A PDT Pioneerover 6 years ago
Data Shape-Up: Striving to Standardizeover 6 years ago
Policy Sync-Up: The Drug Importation Conundrumover 6 years ago
Validating Value Data: AI and Outcomesover 6 years ago
Underlying Platform: Data Unleashedover 6 years ago
Surfing the Wave: The Patient-Data Puzzleover 6 years ago
Where Does Europe’s Drug Industry Go from Here?Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Foundayo and Lower-Dose Zepbound Helped Maintain Weight Loss in Patients Switching from Injectables
2
Beyond the Molecule: The New Competitive Battlefield in Oncology
3
FDA Approves Beqalzi for Relapsed or Refractory Mantle Cell Lymphoma, Inqovi in Combination with Venetoclax
4
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
5




